Bertrand Lell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bertrand Lell has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Peter Gottfried Kremsner
Institute of Tropical Medicine, University Hospital Tübingen, 72074 Tübingen, Germany
10 shared publications Peter G. Kremsner
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
4 shared publications- Martin Peter Grobusch
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
3 shared publications Saadou Issifou
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
3 shared publications- Saadou Issifou
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
3 shared publications - Carmen Lucelly Ospina Salazar
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
2 shared publications
Latest Publications
- Open Access
- 4 March 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 124
Incidence, pathogens and resistance patterns of nosocomial infections at a rural hospital in Gabon
Background: Nosocomial infections pose substantial risk to patients receiving care in hospitals. In Africa, this problem is aggravated by inadequate infection control due to poor hygiene, resource and structural constraints, deficient surveillance data and lack of awareness regarding nosocomial infections. We carried out this study to determine the incidence and spectrum of nosocomial infections, pathogens and antibiotic resistance patterns in a tertiary regional hospital in Lambaréné, Gabon. Methods: This prospective case study was carried out over a period of six months at the Albert Schweitzer Hospital, Lambaréné, Gabon. All patients admitted to the departments of surgery, gynecology/obstetrics and internal medicine were screened daily for signs and symptoms of hospital-acquired infections. Results: A total of 2925 patients were screened out of which 46 nosocomial infections (1.6%) were diagnosed. These comprised 20 (44%) surgical-site infections, 12 (26%) urinary-tract infections, 9 (20%) bacteraemias and 5 (11%) other infections. High rates of nosocomial infections were found after hysterectomies (12%) and Caesarean sections (6%). Most frequent pathogens were Staphylococcus aureus and Escherichia coli. Eight (40%) of 20 identified E. coli and Klebsiella spp. strains were ESBL-producing organisms. Conclusion: The cumulative incidence of nosocomial infections in this study was low; however, the high rates of surgical site infections and multi-resistant pathogens necessitate urgent comprehensive interventions of infection control.
- 4 March 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 124
Open AccessIncidence, pathogens and resistance patterns of nosocomial infections at a rural hospital in Gabon
Background: Nosocomial infections pose substantial risk to patients receiving care in hospitals. In Africa, this problem is aggravated by inadequate infection control due to poor hygiene, resource and structural constraints, deficient surveillance data and lack of awareness regarding nosocomial infections. We carried out this study to determine the incidence and spectrum of nosocomial infections, pathogens and antibiotic resistance patterns in a tertiary regional hospital in Lambaréné, Gabon. Methods: This prospective case study was carried out over a period of six months at the Albert Schweitzer Hospital, Lambaréné, Gabon. All patients admitted to the departments of surgery, gynecology/obstetrics and internal medicine were screened daily for signs and symptoms of hospital-acquired infections. Results: A total of 2925 patients were screened out of which 46 nosocomial infections (1.6%) were diagnosed. These comprised 20 (44%) surgical-site infections, 12 (26%) urinary-tract infections, 9 (20%) bacteraemias and 5 (11%) other infections. High rates of nosocomial infections were found after hysterectomies (12%) and Caesarean sections (6%). Most frequent pathogens were Staphylococcus aureus and Escherichia coli. Eight (40%) of 20 identified E. coli and Klebsiella spp. strains were ESBL-producing organisms. Conclusion: The cumulative incidence of nosocomial infections in this study was low; however, the high rates of surgical site infections and multi-resistant pathogens necessitate urgent comprehensive interventions of infection control.
- Open Access
- 1 July 2012
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 18 (7) , 1206-1207
Buruli Ulcer in Gabon, 2001–2010
- 1 July 2012
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 18 (7) , 1206-1207
Open AccessBuruli Ulcer in Gabon, 2001–2010
- 1 June 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (6) , 3165-3173
Pharmacokinetics of Ferroquine, a Novel 4-Aminoquinoline, in Asymptomatic Carriers of Plasmodium falciparum Infections
Ferroquine (SSR97193), a ferrocene-quinoline conjugate, is a promising novel antimalarial currently undergoing clinical evaluation. This study characterizes its pharmacokinetic properties. Young male African volunteers with asymptomatic Plasmodium falciparum infection were administered a single oral dose ( n = 40) or a repeated oral dose ( n = 26) given over 3 days of ferroquine in two dose-escalation, double-blind, randomized, placebo-controlled clinical trials. In addition, a food interaction study was performed in a subsample of participants ( n = 16). The studies were carried out in Lambaréné, Gabon. After single-dose administration of ferroquine, dose linearity was demonstrated in a dose range of 400 to 1,200 mg for maximum mean blood concentrations ([ C max ] 82 to 270 ng/ml) and in a dose range of 400 to 1,600 mg for overall exposure to ferroquine (area under the concentration-time curve [AUC], 13,100 to 49,200 ng · h/ml). Overall mean estimate for blood apparent terminal half-life of ferroquine was 16 days and 31 days for its active and major metabolite desmethylferroquine (SSR97213). In the 3-day repeated-dose study, C max and overall cumulated exposure to ferroquine (AUC cum ) increased in proportion with the dose from day 1 to day 3 between 400 and 800 mg. No major food effect on ferroquine pharmacokinetics was observed after single administration of 100 mg of ferroquine except for a slight delay of time to maximum blood concentration ( t max ) by approximately 3 h. The pharmacokinetics of ferroquine and its active main metabolite are characterized by sustained levels in blood, and the properties of ferroquine as a partner drug in antimalarial combination therapy should be evaluated.
- 1 June 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (6) , 3165-3173
Pharmacokinetics of Ferroquine, a Novel 4-Aminoquinoline, in Asymptomatic Carriers of Plasmodium falciparum Infections
Ferroquine (SSR97193), a ferrocene-quinoline conjugate, is a promising novel antimalarial currently undergoing clinical evaluation. This study characterizes its pharmacokinetic properties. Young male African volunteers with asymptomatic Plasmodium falciparum infection were administered a single oral dose ( n = 40) or a repeated oral dose ( n = 26) given over 3 days of ferroquine in two dose-escalation, double-blind, randomized, placebo-controlled clinical trials. In addition, a food interaction study was performed in a subsample of participants ( n = 16). The studies were carried out in Lambaréné, Gabon. After single-dose administration of ferroquine, dose linearity was demonstrated in a dose range of 400 to 1,200 mg for maximum mean blood concentrations ([ C max ] 82 to 270 ng/ml) and in a dose range of 400 to 1,600 mg for overall exposure to ferroquine (area under the concentration-time curve [AUC], 13,100 to 49,200 ng · h/ml). Overall mean estimate for blood apparent terminal half-life of ferroquine was 16 days and 31 days for its active and major metabolite desmethylferroquine (SSR97213). In the 3-day repeated-dose study, C max and overall cumulated exposure to ferroquine (AUC cum ) increased in proportion with the dose from day 1 to day 3 between 400 and 800 mg. No major food effect on ferroquine pharmacokinetics was observed after single administration of 100 mg of ferroquine except for a slight delay of time to maximum blood concentration ( t max ) by approximately 3 h. The pharmacokinetics of ferroquine and its active main metabolite are characterized by sustained levels in blood, and the properties of ferroquine as a partner drug in antimalarial combination therapy should be evaluated.
- Open Access
- 17 October 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 305
Cost-effectiveness of intermittent preventive treatment of malaria in infants (IPTi) for averting anaemia in Gabon: a comparison between intention to treat and according to protocol analyses
In Gabon, the impact of intermittent preventive treatment of malaria in infants (IPTi) was not statistically significant on malaria reduction, but the impact on moderate anaemia was, with some differences between the intention to treat (ITT) and the according to protocol (ATP) trial analyses. Specifically, ATP was statistically significant, while ITT analysis was borderline. The main reason for the difference between ITT and ATP populations was migration.
- 17 October 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 305
Open AccessCost-effectiveness of intermittent preventive treatment of malaria in infants (IPTi) for averting anaemia in Gabon: a comparison between intention to treat and according to protocol analyses
In Gabon, the impact of intermittent preventive treatment of malaria in infants (IPTi) was not statistically significant on malaria reduction, but the impact on moderate anaemia was, with some differences between the intention to treat (ITT) and the according to protocol (ATP) trial analyses. Specifically, ATP was statistically significant, while ITT analysis was borderline. The main reason for the difference between ITT and ATP populations was migration.
- Open Access
- 1 March 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 53
Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection
Background: The development and spread of drug resistantPlasmodium falciparumstrains is a major concern and novel anti-malarial drugs are, therefore, needed. Ferroquine is a ferrocenic derivative of chloroquine with proven anti-malarial activity against chloroquine-resistant and -sensitiveP. falciparumlaboratory strains.Methods: Adult young male aged 18 to 45 years, asymptomatic carriers ofP. falciparum, were included in two-dose escalation, double-blind, randomized, placebo-controlled Phase I trials, a single dose study and a multiple dose study aiming to evaluate oral doses of ferroquine from 400 to 1,600 mg.Results: Overall, 54/66 patients (40 and 26 treated in the single and multiple dose studies, respectively) experienced at least one adverse event, 15 were under placebo. Adverse events were mainly gastrointestinal symptoms such as abdominal pain (16), diarrhoea (5), nausea (13), and vomiting (9), but also headache (11), and dizziness (5). A few patients had slightly elevated liver parameters (10/66) including two patients under placebo. Moderate changes in QTc and morphological changes in T waves were observed in the course of the study. However, no adverse cardiac effects with clinical relevance were observed.Conclusions: These phase I trials showed that clinically, ferroquine was generally well-tolerated up to 1,600 mg as single dose and up to 800 mg as repeated dose in asymptomatic young male withP. falciparuminfection. Further clinical development of ferroquine, either alone or in combination with another anti-malarial, is highly warranted and currently underway.
- 1 March 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 53
Open AccessPhase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection
Background: The development and spread of drug resistantPlasmodium falciparumstrains is a major concern and novel anti-malarial drugs are, therefore, needed. Ferroquine is a ferrocenic derivative of chloroquine with proven anti-malarial activity against chloroquine-resistant and -sensitiveP. falciparumlaboratory strains.Methods: Adult young male aged 18 to 45 years, asymptomatic carriers ofP. falciparum, were included in two-dose escalation, double-blind, randomized, placebo-controlled Phase I trials, a single dose study and a multiple dose study aiming to evaluate oral doses of ferroquine from 400 to 1,600 mg.Results: Overall, 54/66 patients (40 and 26 treated in the single and multiple dose studies, respectively) experienced at least one adverse event, 15 were under placebo. Adverse events were mainly gastrointestinal symptoms such as abdominal pain (16), diarrhoea (5), nausea (13), and vomiting (9), but also headache (11), and dizziness (5). A few patients had slightly elevated liver parameters (10/66) including two patients under placebo. Moderate changes in QTc and morphological changes in T waves were observed in the course of the study. However, no adverse cardiac effects with clinical relevance were observed.Conclusions: These phase I trials showed that clinically, ferroquine was generally well-tolerated up to 1,600 mg as single dose and up to 800 mg as repeated dose in asymptomatic young male withP. falciparuminfection. Further clinical development of ferroquine, either alone or in combination with another anti-malarial, is highly warranted and currently underway.
- Open Access
- 29 December 2010
- Published by Wiley in Tropical Medicine & International Health
- Vol. 16 (3) , 343-348
Haematological and biochemical reference intervals for infants and children in Gabon
Summary: Objectives To establish reference intervals for major haematological and biochemical parameters in Gabonese infants and children.Methods The reference sample population consisted of 226 healthy infants (4–9 weeks of age) and 185 healthy children (18–60 months of age). Basic red cell parameters as well as total and differential white blood cell counts were performed. Clinical chemistry parameters consisted of glutamate–pyruvic transaminase and creatinine, and total bilirubin was measured in children. Statistical analysis was based on the guidelines of the Clinical and Laboratory Standards Institute. Nonparametric methods were used to determine 95% reference limits and their 90% confidence intervals.Results Compared to European populations, values for several red cell parameters (haemoglobin, haematocrit, red blood cell count, mean corpuscular volume) were lower and platelet counts were higher. Eosinophils were higher in the older age group, most likely caused by intestinal helminths.Conclusions The study confirms the importance of establishing reference limits for local populations. The reference ranges could be used as a benchmark for similar populations in Central Africa.
- 29 December 2010
- Published by Wiley in Tropical Medicine & International Health
- Vol. 16 (3) , 343-348
Open AccessHaematological and biochemical reference intervals for infants and children in Gabon
Summary: Objectives To establish reference intervals for major haematological and biochemical parameters in Gabonese infants and children.Methods The reference sample population consisted of 226 healthy infants (4–9 weeks of age) and 185 healthy children (18–60 months of age). Basic red cell parameters as well as total and differential white blood cell counts were performed. Clinical chemistry parameters consisted of glutamate–pyruvic transaminase and creatinine, and total bilirubin was measured in children. Statistical analysis was based on the guidelines of the Clinical and Laboratory Standards Institute. Nonparametric methods were used to determine 95% reference limits and their 90% confidence intervals.Results Compared to European populations, values for several red cell parameters (haemoglobin, haematocrit, red blood cell count, mean corpuscular volume) were lower and platelet counts were higher. Eosinophils were higher in the older age group, most likely caused by intestinal helminths.Conclusions The study confirms the importance of establishing reference limits for local populations. The reference ranges could be used as a benchmark for similar populations in Central Africa.
- Open Access
- 21 December 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1) , 368
Pentoxifylline as an adjunct therapy in children with cerebral malaria
Pentoxifylline (PTX) affects many processes that may contribute to the pathogenesis of severe malaria and it has been shown to reduce the duration of coma in children with cerebral malaria. This pilot study was performed to assess pharmacokinetics, safety and efficacy of PTX in African children with cerebral malaria.
- 21 December 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1) , 368
Open AccessPentoxifylline as an adjunct therapy in children with cerebral malaria
Pentoxifylline (PTX) affects many processes that may contribute to the pathogenesis of severe malaria and it has been shown to reduce the duration of coma in children with cerebral malaria. This pilot study was performed to assess pharmacokinetics, safety and efficacy of PTX in African children with cerebral malaria.
- Open Access
- 14 May 2010
- Published by Springer Nature in BMC Genomic Data
- Vol. 11 (1) , 38
Phylogenetic nomenclature and evolution of mannose-binding lectin (MBL2) haplotypes
Background: Polymorphisms of the mannose-binding lectin gene (MBL2) affect the concentration and functional efficiency of the protein. We recently used haplotype-specific sequencing to identify 23MBL2haplotypes, associated with enhanced susceptibility to several diseases.Results: In this work, we applied the same method in 288 and 470 chromosomes from Gabonese and European adults, respectively, and found three new haplotypes in the last group. We propose a phylogenetic nomenclature to standardizeMBL2studies and found two major phylogenetic branches due to six strongly linked polymorphisms associated with high MBL production. They presented high Fst values and were imbedded in regions with high nucleotide diversity and significant Tajima's D values. Compared to others using small sample sizes and unphased genotypic data, we found differences in haplotyping, frequency estimation, Fu and Li's D* and Fst results.Conclusion: Using extensive testing for selective neutrality, we confirmed that stochastic evolutionary factors have had a major role in shaping this polymorphic gene worldwide.
- 14 May 2010
- Published by Springer Nature in BMC Genomic Data
- Vol. 11 (1) , 38
Open AccessPhylogenetic nomenclature and evolution of mannose-binding lectin (MBL2) haplotypes
Background: Polymorphisms of the mannose-binding lectin gene (MBL2) affect the concentration and functional efficiency of the protein. We recently used haplotype-specific sequencing to identify 23MBL2haplotypes, associated with enhanced susceptibility to several diseases.Results: In this work, we applied the same method in 288 and 470 chromosomes from Gabonese and European adults, respectively, and found three new haplotypes in the last group. We propose a phylogenetic nomenclature to standardizeMBL2studies and found two major phylogenetic branches due to six strongly linked polymorphisms associated with high MBL production. They presented high Fst values and were imbedded in regions with high nucleotide diversity and significant Tajima's D values. Compared to others using small sample sizes and unphased genotypic data, we found differences in haplotyping, frequency estimation, Fu and Li's D* and Fst results.Conclusion: Using extensive testing for selective neutrality, we confirmed that stochastic evolutionary factors have had a major role in shaping this polymorphic gene worldwide.
- 1 March 2010
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 122 (S1) , 16-18
Developing Information Technology at the Medical Research Unit of the Albert Schweitzer Hospital in Lambaréné, Gabon
Informationstechnik (IT) ist zu einem zentralen Bereich für Forschungseinrichtungen geworden, mit einem Aufgabenfeld welches von Netzwerkverwaltung, Datenverarbeitung bis hin zu Software Entwicklung reicht. Die IT-Abteilung am Medical Research Unit (MRU) des Albert Schweitzer Krankenhauses in Lambaréné, Gabon zeigt beispielhaft die Entwicklung von IT in Afrikanischen Forschungsinstituten während den letzten Jahren. Weiters verdeutlicht es die Entwicklung in den letzten 15 Jahren, ausgehend vom ersten installierten Computer, bis hin zur derzeitigen Situation mit einer Gruppe von gut ausgebildeten lokalen IT-Fachkräften, die sich verantwortlich zeigen für die Betreuung von Hard- und Software sowie für die Entwicklung von Anwendungen. Quelloffene ("Open Source") Anwendungen sind für die genannten Bedürfnisse besonders geeignet und MRU verwendet diese in den Bereichen Datenmanagement, Datenanalyse, Buchhaltung, Verwaltung und Qualitätsmanagement. Information technology has become a key resource for research institutions, providing services such as hardware, software and network maintenance, as well as data management services. The IT department of the Medical Research Unit (MRU) of the Albert Schweitzer Hospital in Lambaréné, Gabon is a good example of how IT has developed at African Research Centres in recent years and demonstrates the scope of work that a modern research centre needs to offer. It illustrates the development in the past 15 years – from single computers maintained by investigators to the present situation of a group of well-trained local IT personal who are in charge of a variety of hardware and software and who also develop applications for use in a research environment. Open source applications are particularly suited for these needs and various applications are used in data management, data analysis, accounting, administration and quality management.
- 1 March 2010
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 122 (S1) , 16-18
Developing Information Technology at the Medical Research Unit of the Albert Schweitzer Hospital in Lambaréné, Gabon
Informationstechnik (IT) ist zu einem zentralen Bereich für Forschungseinrichtungen geworden, mit einem Aufgabenfeld welches von Netzwerkverwaltung, Datenverarbeitung bis hin zu Software Entwicklung reicht. Die IT-Abteilung am Medical Research Unit (MRU) des Albert Schweitzer Krankenhauses in Lambaréné, Gabon zeigt beispielhaft die Entwicklung von IT in Afrikanischen Forschungsinstituten während den letzten Jahren. Weiters verdeutlicht es die Entwicklung in den letzten 15 Jahren, ausgehend vom ersten installierten Computer, bis hin zur derzeitigen Situation mit einer Gruppe von gut ausgebildeten lokalen IT-Fachkräften, die sich verantwortlich zeigen für die Betreuung von Hard- und Software sowie für die Entwicklung von Anwendungen. Quelloffene ("Open Source") Anwendungen sind für die genannten Bedürfnisse besonders geeignet und MRU verwendet diese in den Bereichen Datenmanagement, Datenanalyse, Buchhaltung, Verwaltung und Qualitätsmanagement. Information technology has become a key resource for research institutions, providing services such as hardware, software and network maintenance, as well as data management services. The IT department of the Medical Research Unit (MRU) of the Albert Schweitzer Hospital in Lambaréné, Gabon is a good example of how IT has developed at African Research Centres in recent years and demonstrates the scope of work that a modern research centre needs to offer. It illustrates the development in the past 15 years – from single computers maintained by investigators to the present situation of a group of well-trained local IT personal who are in charge of a variety of hardware and software and who also develop applications for use in a research environment. Open source applications are particularly suited for these needs and various applications are used in data management, data analysis, accounting, administration and quality management.
- Open Access
- 27 October 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (10) , e7611
A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon
The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water emulsion – based formulation (AS02) and a formulation based on liposomes (AS01). In this Phase II, double-blind study (NCT00307021), 180 healthy Gabonese children aged 18 months to 4 years were randomized to receive either RTS,S/AS01E or RTS,S/AS02D, on a 0–1–2 month vaccination schedule. The children were followed-up daily for six days after each vaccination and monthly for 14 months. Blood samples were collected at 4 time-points. Both vaccines were well tolerated. Safety parameters were distributed similarly between the two groups. Both vaccines elicited a strong specific immune response after Doses 2 and 3 with a ratio of anti-CS GMT titers (AS02D/AS01E) of 0.88 (95% CI: 0.68–1.15) post-Dose 3. After Doses 2 and 3 of experimental vaccines, anti-CS and anti-HBs antibody GMTs were higher in children who had been previously vaccinated with at least one dose of hepatitis B vaccine compared to those not previously vaccinated. RTS,S/AS01E proved similarly as well tolerated and immunogenic as RTS,S/AS02D, completing an essential step in the age de-escalation process within the RTS,S clinical development plan. ClinicalTrials.gov. NCT00307021
- 27 October 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (10) , e7611
Open AccessA Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon
The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water emulsion – based formulation (AS02) and a formulation based on liposomes (AS01). In this Phase II, double-blind study (NCT00307021), 180 healthy Gabonese children aged 18 months to 4 years were randomized to receive either RTS,S/AS01E or RTS,S/AS02D, on a 0–1–2 month vaccination schedule. The children were followed-up daily for six days after each vaccination and monthly for 14 months. Blood samples were collected at 4 time-points. Both vaccines were well tolerated. Safety parameters were distributed similarly between the two groups. Both vaccines elicited a strong specific immune response after Doses 2 and 3 with a ratio of anti-CS GMT titers (AS02D/AS01E) of 0.88 (95% CI: 0.68–1.15) post-Dose 3. After Doses 2 and 3 of experimental vaccines, anti-CS and anti-HBs antibody GMTs were higher in children who had been previously vaccinated with at least one dose of hepatitis B vaccine compared to those not previously vaccinated. RTS,S/AS01E proved similarly as well tolerated and immunogenic as RTS,S/AS02D, completing an essential step in the age de-escalation process within the RTS,S clinical development plan. ClinicalTrials.gov. NCT00307021